Antibody Ingredients TRIZ Cases

Fully human anti-CD123 antibodies target quiescent leukemic stem cells to eliminate residual disease and reduce relapse rates in acute myelogenous leukemia.

Anti-CTLA4 antibodies resolve low targeting specificity by blocking CTLA4 pathways to inhibit tumor growth in melanoma and lung carcinoma.

Collagen antagonists disrupt restrictive tumor stroma to boost CD8+ T-cell infiltration while reducing regulatory T-cell suppression.

Dual-function antibodies bind glycosylated PD-L1 to block PD-1 interaction and promote receptor internalization, reducing immunosuppression.

Engineered antibody CDR mutations increase binding affinity to the extracellular region of human EGFR.

Anti-Claudin-1 antibodies specifically bind Claudin-1 in lungs, kidneys, and skin to reverse poor-prognosis gene signatures and improve serum creatinine levels.

IgG4PE mutations eliminate FcγR binding, resolving hemagglutination while maintaining anti-tumor efficacy.

Modified CAIX antibodies reduce neonatal Fc receptor binding to shorten serum half-life.

Monovalent anti-CD3 Fab fragments bind CD3 receptors to boost tumor antigen immunogenicity, resolving poor immune response against weak antigens.

Integrates immune checkpoint inhibition with cytotoxic agents via preliminary and adjuvant dosing to improve event-free survival against recurrence.

Humanized anti-CD70 antibodies resolve specificity and efficacy trade-offs by sparing non-target cells while mediating cytotoxic effects.

Antibodies bind MICA/B on tumor cells to prevent protease-mediated shedding, reducing soluble levels that suppress NKG2D activity.

Anti-prolactin receptor antibody formulations use optimized excipients to achieve low viscosity at high concentrations while maintaining isosmotic conditions.

Humanized monoclonal antibodies block TIGIT signaling to reverse immune tolerance in cancer and viral infections.

Anti-KLRG1 antibodies block ligand binding to restore T cell cytotoxicity against cancer.

Single domain antibodies target rare heparan sulfate glycans to block DC-HIL signaling, reducing tumor growth and lung metastasis in preclinical models.

Bispecific binding agents target CD8+KIR+ regulatory T cells to modulate immune responses through simultaneous antigen engagement.

Feeder-free production of CD141+CLEC9A+ dendritic cells via FLT3L and GM-CSF resolves low blood prevalence constraints.

Antibodies bind B7-H1 or PD-1 to modulate immune signaling, addressing the lack of effective compositions for cancer therapy.

Combining anti-CD39 antibodies with anti-PD-1 or anti-PD-L1 agents modulates immune responses to enhance T-cell proliferation.

Antigen-binding protein constructs modify binding affinity at acidic pH to enhance endolysosomal delivery and cell killing efficiency.

Bispecific antibodies targeting HER2 and APLP2 resolve inefficient lysosomal trafficking in intermediate HER2-expressing breast cancer cells.

Humanized anti-C5 antibodies bind specific epitopes to inhibit terminal complement activation and reduce tissue injury.

Antigen binding molecules inhibit ADAMTS13 to preserve high molecular weight VWF multimers.

A trispecific antibody arms drugs to target tumor cells and cancer-associated fibroblasts simultaneously.

Optimized antibody binding pocket achieves picomolar affinity to neutralize fentanyl pharmacological activity at low dosages.

Optimized CDR sequences in antibody variable domains increase binding affinity to PD-L1, restoring immune surveillance against tumors.

Isolated human antibodies bind specifically to activated protein C to modulate its biological functions.

Combining a HER3 blocker with an immune checkpoint modulator reverses the immunosuppressive tumor microenvironment in head and neck cancer.

Enzymatic assembly replaces heterogeneous mammalian cell culture processes to resolve manufacturing precision issues and ensure consistent therapeutic efficacy.

Fusion molecules target epidermal antigens to treat pemphigus vulgaris without widespread immune suppression.

Antibodies against CD4, CD8, and CD40L induce immunotolerance to prevent immune rejection of human pluripotent stem cell grafts.

Soluble CD27 measurement predicts immune dysfunction caused by CD27-CD70 interactions, enabling targeted RCC therapy.

Establishing the OSW cell line resolves validation difficulties by enabling reliable preclinical testing of canine therapies and human lymphoma research.

Removing core fucose eliminates hemagglutination while preserving antibody binding and anti-tumor efficacy.

Anti-third party cytotoxic T lymphocytes prevent immune rejection and graft versus host disease during cell therapy.

Anti-Flt-1 antibodies block Flt-1 receptor binding to increase VEGF availability, reducing lung inflammation and scarring in premature infants.

Antibodies bind to specific alpha-subunit epitopes on the NaK-ATPase enzyme to modulate cardiac contraction.

Multispecific antibodies merge CD47 targeting with EpCAM recognition to enhance phagocytosis while minimizing hemolysis from normal cell interaction.

Amlexanox induces neoantigen expression on tumor cells to resolve the contradiction between immune activation and treatment efficacy in late-stage cancers.

Centrifugation and filtration remove these aggregates alongside residual antibodies, ensuring erythrocyte concentrate purity for safe reinfusion.

Modified anti-CD47 antibodies utilize cell-free expression to increase yield and reduce glycosylation.

Engineered antibody fragments exploit receptor-mediated transcytosis to cross the blood-brain barrier.

Humanized antibodies target human OX40 receptors on T cells to resolve cross-reactivity with murine proteins while maintaining high binding affinity.

Anti-SIRPg antibodies inhibit CD47 binding to reduce T cell proliferation, mitigating autoimmune disorder severity.

Antibodies targeting the CD47 IgV domain inhibit TSP1 and SIRPalpha binding, resolving off-target effects while promoting cancer cell clearance.

Human autoimmune antibodies target necrotic tumor areas to deliver drugs without triggering patient immune responses, resolving immunogenicity trade-offs.

Merges three agents with distinct mechanisms to overcome monotherapy limits and enhance anti-tumor efficacy in advanced cancers.

Detecting antibodies against NR1 and NR2 subunits of the NMDA receptor in body fluids resolves diagnostic reliability issues by pinpointing autoimmune etiology.